PAION turns to Philips for Phase 2 and 3 of clinical trials
PAION AG, a Germany-based biopharmaceutical company, will use Philips Medical Systems' brain perfusion CT software package in conjunction with its Phase II and Phase III clinical trials for its investigational drug Desmoteplase.
The software will be used to assist PAION in their determination of the safety and effectiveness of Desmoteplase in the treatment of stroke patients. The software displays summary maps, which make it possible to distinguish between still-viable and non-viable infarcted tissue and includes quantitative color maps of cerebral blood flow, cerebral blood volume, mean transit time and time-to-peak. These provide valuable clinical information for treatment planning and assisting clinicians in making reasonably accurate predictions as to which individual patients may benefit from reperfusion therapy, PAION said.
Desmoteplase, first in a new class of plasminogen activators, is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat, Desmodus rotundus. Earlier this year, PAION presented positive results from a Phase II trial demonstrating the compound's potential to treat patients up to nine hours after the onset of stroke symptoms. Desmoteplase will be developed and marketed in North America by Forest Laboratories Inc. and was recently granted fast track status by the U.S. FDA, said PAION.
The software will be used to assist PAION in their determination of the safety and effectiveness of Desmoteplase in the treatment of stroke patients. The software displays summary maps, which make it possible to distinguish between still-viable and non-viable infarcted tissue and includes quantitative color maps of cerebral blood flow, cerebral blood volume, mean transit time and time-to-peak. These provide valuable clinical information for treatment planning and assisting clinicians in making reasonably accurate predictions as to which individual patients may benefit from reperfusion therapy, PAION said.
Desmoteplase, first in a new class of plasminogen activators, is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat, Desmodus rotundus. Earlier this year, PAION presented positive results from a Phase II trial demonstrating the compound's potential to treat patients up to nine hours after the onset of stroke symptoms. Desmoteplase will be developed and marketed in North America by Forest Laboratories Inc. and was recently granted fast track status by the U.S. FDA, said PAION.